Korea New Pharmaceuticals

Korea New Pharmaceutical is a South Korean pharmaceutical company established in 1961 that specializes in the integration of traditional Korean medicine with modern pharmaceutical science. The company is best known for developing Meskima, an immunostimulant derived from the Phellinus linteus mushroom, which is used as an adjunct treatment for cancer patients. Their product portfolio includes a wide range of herbal extracts, over-the-counter medications, and prescription drugs targeting digestive, respiratory, and circulatory health. Korea New Pharmaceutical operates significant manufacturing facilities in South Korea and maintains a focus on standardized herbal medicine production. The company continues to research natural products to develop new therapeutic agents for chronic and hard-to-treat diseases.